{
    "pmid": "41471277",
    "title": "Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.",
    "abstract": "The RAS family of oncoproteins (KRAS, HRAS, and NRAS) drive aggressive cancers like pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), yet targeting mutant RAS has historically been challenging due to its \"undruggable\" structure. Recent advances in mutation-specific inhibitors (e.g., sotorasib for KRAS",
    "disease": "lung cancer",
    "clean_text": "broad spectrum ras inhibition in pancreatic ductal adenocarcinoma mechanistic advances and therapeutic promise the ras family of oncoproteins kras hras and nras drive aggressive cancers like pancreatic ductal adenocarcinoma pdac and non small cell lung cancer nsclc yet targeting mutant ras has historically been challenging due to its undruggable structure recent advances in mutation specific inhibitors e g sotorasib for kras"
}